# US 2020/0368355 A1 · Formulations of bendamustine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368355 A1
- Document ID: US20200368355A1
- Status: Published application
- Kind: A1
- Application number: 16/696,421
- Filed: 2019-11-26
- Published: 2020-11-26
- Earliest claimed: 2012-03-20
- Assignees: Eagle Pharmaceuticals, Inc.
- Applicants: Eagle Pharmaceuticals, Inc.
- Inventors: Srikanth Sundaram
- Web page: https://patentgrep.com/patent/US20200368355A1

## CPC

- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 47/02: Inorganic compounds
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.

## Claims

### Claim 1

A method of treating chronic lymphocytic leukemia or indolent B cell non-Hodgkin's lymphoma in a subject comprising parenterally administering to the subject a volume of about 100 mL or less of a liquid composition comprising:
bendamustine;
a charged cyclopolysaccharide; and
a parenterally acceptable diluent;
over a period of less than or equal to about 15 minutes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 3 (depends on 1)

The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt thereof is from about 0.05 to about 12.5 mg/mL.

### Claim 4 (depends on 1)

The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt thereof is from about 0.1 to about 6.0 mg/mL.

### Claim 5 (depends on 1)

The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt thereof is from about 0.05 to about 3.2 mg/mL.

### Claim 6 (depends on 1)

The method of claim 1, wherein the concentration of the bendamustine or pharmaceutically acceptable salt thereof is from about 0.5 to about 5.6 mg/mL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the volume administered is about 100 ml, about 50 mL, about 30 mL, or about 5 mL.

### Claim 8 (depends on 1)

The method of claim 1, wherein the volume administered is about 50 mL.

### Claim 9 (depends on 1)

The method of claim 1, wherein the bendamustine is administered to treat chronic lymphocytic leukemia.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition is administered intravenously in a volume of about 50 mL in about 10 minutes or less on days 1 and 2 of a 28 day cycle.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is administered in about 10 minutes.

### Claim 12 (depends on 10)

The method of claim 10, wherein the composition is administered for up to 6 cycles.

### Claim 13 (depends on 9)

The method of claim 9, wherein the volume of the composition administered to the subject provides a bendamustine dosage amount ranging from about 25 mg/m2 to about 100 mg/m2 to the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition provides a bendamustine dosage of about 100 mg/m2.

### Claim 15 (depends on 9)

The method of claim 9, wherein the liquid composition comprises from about 1.85 mg/mL to about 4.84 mg/mL of bendamustine or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the bendamustine is administered to treat indolent B cell non-Hodgkin's lymphoma.

### Claim 17 (depends on 16)

The method of claim 16, wherein the composition is administered intravenously in a volume of about 50 mL in about 10 minutes or less on days 1 and 2 of a 21 day cycle.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition is administered in about 10 minutes.

### Claim 19 (depends on 17)

The method of claim 17, wherein the composition is administered for up to 8 cycles.

### Claim 20 (depends on 16)

The method of claim 16, wherein the volume of the composition administered to the subject provides a bendamustine dosage amount ranging from about 60 mg/m2 to about 120 mg/m2 to the subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein the composition provides a bendamustine dosage of about 120 mg/m2.

### Claim 22 (depends on 16)

The method of claim 16, wherein the liquid composition comprises from about 2.19 mg/mL to about 5.59 mg/mL of bendamustine or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

The method of claim 1, wherein the cyclopolysaccharide is a beta-cyclodextrin.

### Claim 24 (depends on 1)

The method of claim 1, wherein the charged cyclopolysaccaride has one or more anionic groups.

### Claim 25 (depends on 24)

The method of claim 24, wherein the anionic group is a sulfate, sulfonyl, or carbonyl group.

### Claim 26 (depends on 24)

The method of claim 24, wherein the anionic group is a sulfate or sulfonyl group.

### Claim 27 (depends on 24)

The method of claim 24, wherein the cyclopolysaccharide is sulfobutyl ether beta-cyclodextrin.

### Claim 28 (depends on 1)

The method of claim 1, wherein the proportion of bendamustine to cyclopolysaccaride is between about 1:12,500 and about 1:25, by weight.

### Claim 29 (depends on 1)

The method of claim 1, wherein the composition further comprises a stabilizing agent.

### Claim 30 (depends on 29)

The method of claim 29, wherein the stabilizing agent is a polypeptide comprising from about 5 to about 50 amino acids, wherein at least about 50% of the amino acids have a positive charge.

### Claim 31 (depends on 29)

The method of claim 29, wherein the stabilizing agent is a polypeptide comprising between about 6 and about 20 amino acids, wherein at least about 50% of the amino acids have a positive charge.

### Claim 32 (depends on 30)

The method of claim 30, wherein the polypeptide comprises at least one block sequence of 4 arginines.

### Claim 33 (depends on 32)

The method of claim 32, wherein the stabilizing agent is polyarginine.

### Claim 34 (depends on 30)

The method of claim 30, wherein the stabilizing agent is low molecular weight protamine.

### Claim 35 (depends on 1)

The method of claim 1, wherein the charged group on the cyclopolysaccharide is a cationic group.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the cationic group is a quaternary ammonium group.

### Claim 37 (depends on 1)

The method of claim 1, wherein the bendamustine is present as the hydrochloride salt.
